Key result
Concurrent administration of clopidogrel and omeprazole in healthy cats lowered plasma clopidogrel active metabolite concentrations on day 10 (P<0.02) but did not alter platelet function.
Why the study?
Concurrent clopidogrel and omeprazole decreases clopidogrel active metabolite concentrations and antiplatelet effects in humans, but whether this interaction occurs in cats is unknown.
Does concurrent omeprazole administration alter clopidogrel metabolism and platelet function in healthy cats?
RCT (n=10)
Randomized crossover
Does concurrent omeprazole administration alter clopidogrel metabolism and platelet function in healthy cats?
In healthy cats, concurrent short-term administration of omeprazole and clopidogrel alters clopidogrel pharmacokinetics but does not significantly affect its antiplatelet pharmacodynamics.
Answers are grounded in this paper and cite their sources.
May reduce clopidogrel metabolite exposure in cats without affecting platelet function; leaves open clinical relevance in feline patients.
BACKGROUND: Some studies in humans show that the concurrent use of clopidogrel and omeprazole decreases plasma clopidogrel active metabolite (CAM) concentrations and clopidogrel antiplatelet effects. Whether this drug interaction occurs in cats is unknown. HYPOTHESIS: We hypothesized that administration of clopidogrel with omeprazole would decrease plasma CAM concentrations and decrease clopidogrel antiplatelet effects in healthy cats. ANIMALS: Ten domestic cats. METHODS: In this 2-sequence, 2-period, 2-treatment randomized crossover study, healthy cats were randomly assigned to receive clopidogrel only (18.75 mg PO q24h) or clopidogrel with omeprazole (1 mg/kg PO q12h) for 10 days, followed by a 2-week washout period, and then the opposite treatment for another 10 days. Blood was collected by jugular venipuncture on days 0, 5, and 10. Plasma CAM concentrations were measured using high-performance liquid chromatography-tandem mass spectrometry. Platelet function was evaluated using Plateletworks, Multiplate Analyzer, and Platelet Function Analyzer-100 (PFA-100). RESULTS: Multiplate Analyzer and PFA-100 detected no difference in platelet function between days or treatment groups. Plateletworks detected a significant difference (P < .001) in platelet function from day 0 to 5 and day 0 to 10 in both treatment groups but no difference between treatment groups. Plasma CAM concentrations were significantly lower on day 10 (P < .02) in cats receiving both medications versus clopidogrel only. CONCLUSIONS AND CLINICAL IMPORTANCE: Concurrent omeprazole and clopidogrel administration was associated with altered pharmacokinetics on day 10, but no difference in pharmacodynamics between the 2 treatment groups. The short-term use of clopidogrel and omeprazole does not seem to alter platelet function significantly.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2024) conducted an RCT in Healthy cats (n=10). Clopidogrel with omeprazole vs. Clopidogrel only (18.75 mg PO q24h) was evaluated on Platelet function and plasma clopidogrel active metabolite (CAM) concentrations (p=<.02). Concurrent administration of clopidogrel and omeprazole in healthy cats lowered plasma clopidogrel active metabolite concentrations on day 10 (P<0.02) but did not alter platelet function.
Synapse has enriched 10 related papers. Consider them for comparative context: